Enclomiphene Citrate Patent Field and Generic Timeline

What Is Enclomiphene Citrate and How Does It Work?

Enclomiphene citrate is the (E)-isomer of clomiphene citrate, purified away from its estrogenic sister compound zuclomiphene. It works by occupying hypothalamic estrogen receptors without activating them, which removes the negative-feedback brake on gonadotropin-releasing hormone (GnRH) pulses. The pituitary responds with higher luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and the testes produce more testosterone endogenously.

The Isomer Problem With Standard Clomiphene

Racemic clomiphene citrate contains roughly 62% zuclomiphene and 38% enclomiphene [1]. Zuclomiphene carries a half-life exceeding 30 days and accumulates with repeated dosing, contributing to mood changes, visual disturbances, and estrogenic side effects [1]. Enclomiphene's half-life is approximately 10 hours, so it clears before the next dose and does not accumulate to the same degree [2].

Receptor Binding and the HPG Axis

At the hypothalamus, enclomiphene competes with endogenous estradiol at estrogen receptor alpha (ERα). The occupied receptor cannot transmit the estradiol signal that would otherwise suppress GnRH secretion. Within days of starting 25 mg daily, serum LH roughly doubles and total testosterone rises into the normal male range (300 to 1,000 ng/dL) in men with secondary hypogonadism [3].

Because this mechanism preserves the entire hypothalamic-pituitary-gonadal (HPG) axis, the testes continue to receive FSH stimulation. Intratesticular testosterone, which is required for spermatogenesis, stays high. This contrasts sharply with exogenous testosterone, which suppresses LH and FSH within days and can reduce sperm concentration to zero within three to six months [4].

Clinical Evidence: Kim et al. 2016

Kim et al. Randomized 12 men with secondary hypogonadism to enclomiphene citrate and reported that mean serum testosterone rose from a baseline of 232 ng/dL to 498 ng/dL after 90 days, while sperm concentration was maintained throughout the study period [3]. The study is small, but it is the most-cited controlled dataset demonstrating the fertility-preservation advantage over testosterone gels.

A larger phase III program by Repros Therapeutics (the ZA-301, ZA-302, and ZA-304 trials, each enrolling 100 to 200 men) showed mean testosterone normalization rates of 75 to 85% with 25 mg daily, compared with 14 to 18% on placebo [5].

Enclomiphene Citrate FDA Regulatory History

The FDA review of Androxal is a case study in how post-marketing requirements can kill a commercially viable molecule. Repros Therapeutics submitted its first NDA in 2013, received a Complete Response Letter (CRL), resubmitted, and received a second CRL in 2016.

Why the FDA Rejected Androxal Twice

The agency did not dispute enclomiphene's ability to raise testosterone. Both CRLs centered on cardiovascular safety data requirements. Following the 2010 FDA Drug Safety Communication on testosterone products and the 2014 testosterone meta-analysis published in PLOS ONE (N=27 randomized trials), the FDA required any new testosterone-raising drug to either carry a cardiovascular warning or complete a long-term cardiovascular outcomes trial [6].

Repros argued that enclomiphene's mechanism, raising endogenous testosterone rather than delivering exogenous hormone, made the same risk profile inapplicable. The FDA disagreed on the available evidence, and Repros lacked the capital to fund a cardiovascular outcomes trial that would have enrolled thousands of men for three to five years [5].

Current FDA Status as of 2025

No NDA for enclomiphene citrate is active as of July 2025. The drug appears on no FDA Orange Book approved-products list. Because no approved drug exists, the Hatch-Waxman Act's generic-drug pathway (ANDA filing against a reference listed drug) cannot be used. A generic manufacturer would need to file its own 505(b)(1) NDA or a 505(b)(2) application citing published literature and any still-valid Repros data.

Patent Field: What Is Protected and What Has Expired

Understanding enclomiphene's patent situation requires separating three patent categories: composition of matter, method of use, and formulation patents.

Composition-of-Matter Patents

Enclomiphene citrate as a chemical entity is not novel. Clomiphene citrate itself was first synthesized in the early 1960s, and U.S. Patent 3,848,030 covering racemic clomiphene expired decades ago. Enclomiphene citrate, as the trans-isomer of a known compound, has also been in the chemical literature since at least the 1970s. No currently active composition-of-matter patent covers the enclomiphene molecule itself.

Repros held patents specifically directed at methods of treating secondary hypogonadism with purified enclomiphene, most notably U.S. Patent 7,696,209 (issued 2010, directed at treating testosterone deficiency with trans-clomiphene) and related filings [7]. A 20-year patent term from the priority date of roughly 2003 places expiration around 2023 for those filings, meaning they have now lapsed or will lapse imminently.

Method-of-Use Patents

Method-of-use patents can extend commercial exclusivity even when the molecule itself is old. Repros filed method patents on specific dosing regimens (12.5 mg and 25 mg once-daily oral dosing in men with secondary hypogonadism and a BMI <40 kg/m²) and on preserving fertility while treating hypogonadism. Because no branded drug was ever approved and launched, these patents were never listed in the FDA Orange Book, which means they carry no regulatory exclusivity protection and cannot trigger the 30-month stay that normally delays generic entry.

Method patents can still be enforced in civil court against generic manufacturers, but without Orange Book listing, a generic company faces only patent litigation risk, not automatic regulatory delay. Given that Repros no longer operates as an active pharmaceutical company (it was acquired by Allergan in 2017 and the enclomiphene program was subsequently shelved), the practical enforcement risk is low.

Formulation and Crystalline-Form Patents

Repros also held patents on specific crystalline polymorphs and capsule formulations of enclomiphene citrate. These are narrower claims. Even if valid, they cover only specific physical forms of the drug, not the active ingredient itself. Compounding pharmacies using a different salt form or a differently prepared powder are unlikely to infringe these claims.

Generic Timeline: Realistic Expectations

No FDA-approved generic enclomiphene citrate product exists, and the path to one is non-trivial. Here is the realistic scenario for each possible route.

Route 1: 505(b)(2) NDA Filed by a Generic Sponsor

A pharmaceutical company could file a 505(b)(2) NDA relying on published data (including the Repros trial data that is now in the public domain through FDA advisory committee transcripts and published literature) plus its own bioequivalence and safety studies. This route requires FDA acceptance of the application, a standard 10-month review clock, and resolution of any remaining patent claims.

Given that the molecule has a well-understood safety profile from the clomiphene literature and from Repros's own trials, a 505(b)(2) could be the fastest path. Realistically, even if a sponsor filed tomorrow, approval would not arrive before 2027 at the earliest.

Route 2: New 505(b)(1) NDA

A full NDA with original clinical data would take five to eight years. No company appears to be pursuing this as of 2025.

Route 3: Compounding Under 503A and 503B

This is where enclomiphene citrate actually lives right now. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed pharmacies may compound drugs for individual patients when a valid prescription exists and the drug is not a copy of a commercially available approved drug [8]. Because no approved enclomiphene product exists, 503A pharmacies can legally compound it.

Section 503B outsourcing facilities may also compound enclomiphene without patient-specific prescriptions, provided the drug is not on the FDA's Demonstrably Difficult to Compound list and other conditions are met [8].

The FDA has not placed enclomiphene on its list of drugs that may not be compounded (the "section 503A bulkdrug substances" list), so compounding remains the primary legal access route in 2025.

Enclomiphene vs. Testosterone Replacement Therapy: Clinical Decision Points

For men with secondary hypogonadism who want to preserve fertility or testicular volume, enclomiphene is the more logical choice than exogenous testosterone. Exogenous testosterone suppresses gonadotropins via negative feedback, reducing intratesticular testosterone to levels that can impair spermatogenesis [4].

Testosterone and Sperm Suppression Data

The WHO's multinational study on testosterone as a male contraceptive showed sperm suppression to <3 million/mL in 98.6% of participants receiving 200 mg testosterone enanthate weekly [9]. That degree of suppression is usually reversible, but recovery can take 6 to 18 months after stopping, and a minority of men show incomplete recovery [9].

Enclomiphene avoids this entirely because it does not suppress the HPG axis. FSH remains elevated or normal, the Sertoli cells continue to support spermatogenesis, and intratesticular testosterone is maintained through endogenous LH stimulation.

When Exogenous Testosterone Remains Preferable

Men who have completed their families and want consistent, predictable testosterone levels without the need for daily pill-taking may still prefer injectable or transdermal testosterone. FDA-approved testosterone products have a larger post-marketing safety database, established dosing algorithms, and insurer coverage that compounded enclomiphene cannot match.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends testosterone therapy as first-line for most men with confirmed hypogonadism, while acknowledging that selective estrogen receptor modulators are "reasonable alternatives" in men who want to maintain fertility [10].

Monitoring Parameters for Enclomiphene Users

Clinicians prescribing compounded enclomiphene should check serum total testosterone, LH, FSH, and estradiol at baseline and at four to six weeks after starting therapy. Target total testosterone is 400 to 700 ng/dL for most men. If estradiol rises above 40 pg/mL and the patient is symptomatic, dose reduction to 12.5 mg daily is the first adjustment. Hematocrit should be checked at three months because any testosterone-raising intervention can stimulate erythropoiesis [10].

Dosing, Formulation, and Compounding Considerations

Standard compounded enclomiphene comes in 12.5 mg and 25 mg oral capsules. The 25 mg once-daily dose was the primary dose in the Repros phase III trials [5]. Some clinicians start at 12.5 mg to reduce the chance of estradiol-related side effects before titrating up.

Oral bioavailability data from the Repros program showed a Tmax of approximately two to three hours and a half-life of approximately 10 hours, consistent with once-daily dosing producing steady-state within two to three days [2]. Taking the capsule with food slightly increases Cmax but does not meaningfully change overall exposure.

Compounding pharmacies using enclomiphene citrate bulk powder should source from suppliers with USP or comparable certificates of analysis to confirm the trans-to-cis isomer ratio. A product contaminated with excess zuclomiphene will accumulate over time and partially negate the short half-life advantage that makes enclomiphene preferable to racemic clomiphene.

Safety Profile and Adverse Effects

Enclomiphene's side-effect profile is considerably cleaner than racemic clomiphene's, but not without risk.

Known Adverse Effects

Visual disturbances (blurred vision, photophobia) occur in roughly 1 to 3% of users, consistent with the clomiphene class effect. These should prompt immediate discontinuation and ophthalmologic evaluation, as cases of irreversible visual field loss have been reported with prolonged clomiphene-class use [1].

Elevated estradiol is possible if the testosterone rise is strong. At 25 mg daily, roughly 10 to 15% of men in Repros trials had estradiol above 40 pg/mL [5]. Adding an aromatase inhibitor such as anastrozole 0.5 mg twice weekly is an off-label option in those cases, though it adds another unmonitored variable.

Mood changes, including irritability and emotional lability, appear less common than with racemic clomiphene but are reported anecdotally in clinical practice.

What Is Not Yet Known

Long-term cardiovascular data for enclomiphene specifically are absent. This was the FDA's central concern. Observational data on testosterone therapy suggest a possible signal for increased hematocrit and polycythemia, and the same plausible mechanism exists for enclomiphene, given that it raises endogenous testosterone [6]. Men using compounded enclomiphene for more than 12 months should have periodic cardiovascular risk assessment.

The Compounding Market and Prescribing Field in 2025

Because no approved product exists, enclomiphene citrate occupies an unusual regulatory space. Demand has grown substantially alongside the broader men's health and testosterone-optimization market. Telehealth platforms, including direct-to-consumer hormone clinics, have made compounded enclomiphene accessible to men who either cannot get a traditional office referral or prefer an oral alternative to injections.

The FDA has not taken enforcement action against 503A or 503B compounding of enclomiphene citrate as of the date of this article. However, the agency retains authority to add any drug to its bulk drug substances list, which would effectively end legal compounding. Clinicians and patients should watch the FDA docket for any proposed rulemaking in this area.

Prescribers should document the medical necessity of compounded enclomiphene in the patient record, confirm a secondary (hypothalamic or pituitary) cause of hypogonadism (rather than primary testicular failure, where LH is already elevated), and note that no FDA-approved version of this specific drug is available.